Teva Can Launch Neupogen Biosimilar One Month Before Patent Expiration
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a settlement with Amgen, Teva can begin selling its G-CSF product in November 2013; the launch may be sooner if a third party launches or wins an infringement suit.
You may also be interested in...
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
Teva is the first company to get FDA approval of a version of Amgen’s Neupogen; one biosimilar expert questions why Teva did not switch its BLA to a biosimilar application when that pathway became available.
Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble
FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.
Roche Can Launch Mircera 10 Months Before Amgen's EPO Patent Expires
Amgen inked a license agreement with Roche in settling its patent infringement suit.